Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN) following 2026 MDA conference
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $39.00 price target on Dyne Therapeutics (NASDAQ: DYN)The analyst commented, "We're ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
